The Asia Pacific Recombinant Proteins Market should witness market growth of 11.4% CAGR during the forecast period (2022-2028).
Prokaryotic recombinant proteins are proteins that have been cloned in a prokaryotic system and encoded by a gene (recombinant DNA) (E.coli). Prokaryotic recombinant proteins are a good choice for chronic therapy for a number of autoimmune illnesses due to their high specificity and low immunogenicity.
The recombinant protein market is dominated by monoclonal antibodies. The World Health Organization (WHO) predicts that by 2030, chronic diseases like diabetes, cancer, cardiovascular disease, and others will overtake all other causes of death to rank seventh globally. Because prokaryotic recombinant proteins have more advantages and less adverse effects when treating autoimmune and chronic diseases, this will propel the market for these proteins to increase.
The rising geriatric population within regional nations is one of the main factors driving an increase in the utilisation of protein therapies. Chinese citizens accounted up 18% of the world's population in 2019, the National Library of Medicine reports, with 164.5 million of them aged 65 or older and 26 million being 80 or more. The expansion of the recombinant protein market in this region is projected to be aided by the creation of new products and partnership initiatives by biotechnology firms.
The China market dominated the Asia Pacific Recombinant Proteins Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $195.1 million by 2028. The Japan market is estimated to grow a CAGR of 10.7% during (2022-2028). Additionally, The India market would experience a CAGR of 12.1% during (2022-2028).
Based on Product, the market is segmented into Growth Factors & Chemokines, Recombinant Metabolic Enzymes, Adhesion Molecules & Receptors, Structural Proteins, Membrane Proteins, Kinase Proteins & Regulatory Proteins, Immune Response Proteins, and Others. Based on End-user, the market is segmented into Pharmaceutical & Biopharmaceutical Companies, Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, and Others. Based on Application, the market is segmented into Drug Discovery & Development, Academic Research Studies, Biopharmaceutical Production, Diagnostics, Biotechnology Research, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Techne Corporation, Thermo Fisher Scientific, Inc., Merck Group, Bio-Rad Laboratories, Inc., Abcam plc, Genscript Biotech Corporation, Miltenyi Biotec B.V. & Co. KG, Proteintech Group, Inc., BPS Bioscience, Inc., and RayBiotech Life, Inc.
Prokaryotic recombinant proteins are proteins that have been cloned in a prokaryotic system and encoded by a gene (recombinant DNA) (E.coli). Prokaryotic recombinant proteins are a good choice for chronic therapy for a number of autoimmune illnesses due to their high specificity and low immunogenicity.
The recombinant protein market is dominated by monoclonal antibodies. The World Health Organization (WHO) predicts that by 2030, chronic diseases like diabetes, cancer, cardiovascular disease, and others will overtake all other causes of death to rank seventh globally. Because prokaryotic recombinant proteins have more advantages and less adverse effects when treating autoimmune and chronic diseases, this will propel the market for these proteins to increase.
The rising geriatric population within regional nations is one of the main factors driving an increase in the utilisation of protein therapies. Chinese citizens accounted up 18% of the world's population in 2019, the National Library of Medicine reports, with 164.5 million of them aged 65 or older and 26 million being 80 or more. The expansion of the recombinant protein market in this region is projected to be aided by the creation of new products and partnership initiatives by biotechnology firms.
The China market dominated the Asia Pacific Recombinant Proteins Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $195.1 million by 2028. The Japan market is estimated to grow a CAGR of 10.7% during (2022-2028). Additionally, The India market would experience a CAGR of 12.1% during (2022-2028).
Based on Product, the market is segmented into Growth Factors & Chemokines, Recombinant Metabolic Enzymes, Adhesion Molecules & Receptors, Structural Proteins, Membrane Proteins, Kinase Proteins & Regulatory Proteins, Immune Response Proteins, and Others. Based on End-user, the market is segmented into Pharmaceutical & Biopharmaceutical Companies, Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, and Others. Based on Application, the market is segmented into Drug Discovery & Development, Academic Research Studies, Biopharmaceutical Production, Diagnostics, Biotechnology Research, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Techne Corporation, Thermo Fisher Scientific, Inc., Merck Group, Bio-Rad Laboratories, Inc., Abcam plc, Genscript Biotech Corporation, Miltenyi Biotec B.V. & Co. KG, Proteintech Group, Inc., BPS Bioscience, Inc., and RayBiotech Life, Inc.
Scope of the Study
By Product
- Growth Factors & Chemokines
- Recombinant Metabolic Enzymes, Adhesion Molecules & Receptors
- Structural Proteins
- Membrane Proteins
- Kinase Proteins & Regulatory Proteins
- Immune Response Proteins
- Others
By End-user
- Pharmaceutical & Biopharmaceutical Companies
- Biotechnology Companies
- Academic Research Institutes
- Contract Research Organizations
- Others
By Application
- Drug Discovery & Development
- Academic Research Studies
- Biopharmaceutical Production
- Diagnostics
- Biotechnology Research
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Bio-Techne Corporation
- Thermo Fisher Scientific, Inc.
- Merck Group
- Bio-Rad Laboratories, Inc.
- Abcam plc
- Genscript Biotech Corporation
- Miltenyi Biotec B.V. & Co. KG
- Proteintech Group, Inc.
- BPS Bioscience, Inc.
- RayBiotech Life, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. Asia Pacific Recombinant Proteins Market by Product
Chapter 5. Asia Pacific Recombinant Proteins Market by End User
Chapter 6. Asia Pacific Recombinant Proteins Market by Application
Chapter 7. Asia Pacific Recombinant Proteins Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Bio-Techne Corporation
- Thermo Fisher Scientific, Inc.
- Merck Group
- Bio-Rad Laboratories, Inc.
- Abcam plc
- Genscript Biotech Corporation
- Miltenyi Biotec B.V. & Co. KG
- Proteintech Group, Inc.
- BPS Bioscience, Inc.
- RayBiotech Life, Inc.
Methodology
LOADING...
Related Reports
From
Recombinant Proteins Global Market Report 2024
- Report
- 200 Pages
- Global
From
Recombinant Proteins Market by Product, Services, End-User, Function - Global Forecast 2025-2030
- Report
- 185 Pages
- Global
From
From
Recombinant Protein Market Report by Product, Application, End User, and Region 2024-2032
- Report
- 137 Pages
- Global
From
This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a market research report. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF. This product is a market research report. This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF. 
